NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

1954.00 -5.30 (-0.27%)

95,470 NSE+BSE Volume

NSE 13 Oct, 2025 10:36 AM (IST)

89,250.5

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Lupin Ltd.

06 Nov 2020

1954.00

-0.27%

Q2FY21 Result Update - Albuterol, Glumetza to be catalyst in 2H - BUY

Buy: Lupin Ltd.

Target

Prabhudas Lilladhar

India formulation remained muted with 1% YoY decline. We reduce our earnings estimate by 7% as we revise our EBITDAM lower to 16% (earlier 19%) for FY21E on the back of increased operating expense. 2QFY21 earnings were below our estimate even with most of the regions except India witnessed good growth. The disappointment was primarily at EBITDA level due to increase in operating expense of 34% QoQ, which led EBITDAM of 14% v/s our estimate of 20%. LPC guided for 18.5% EBITDAM for...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

06 Nov 2020

1954.00

-0.27%

Profitability on an uptrend for three quarters now

Buy: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered in-line 2QFY21 results. The EBITDA margin has been on an uptrend since hitting all-time lows in 3QFY20, led by cost rationalization, better-than-industry growth in Domestic Formulations (DF), and improved traction in the US/API segment. Near- to medium-term performance is expected to strengthen further on account of recently launched niche products and better operating leverage. We lower our EPS estimate by 5% for FY21, factoring in a gradual increase in Albuterol Sulfate offtake. We maintain our FY22 estimate and introduce...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

06 Nov 2020

1954.00

-0.27%

Lupin Ltd

Hold: Lupin Ltd.

Target

ICICI Securities Limited

Q2FY21 revenues and operational performance were in-line with I-direct estimates while profitability was below expectations due to below expected other income and a higher tax outgo. As per the management, FY21 US sales would be largely driven by gLevothyroxine, gProAir ramp-up and 15+ new launches. Domestic branded formulations are expected to remain stable. Structurally, the resolution of warning letter and clearance of official action indicated (OAIs) status on plants could be the near term lever along with progress on margins front. Like other pharma majors, Lupin has also...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

05 Nov 2020

1954.00

-0.27%

Lupin (ADD): Muted Q2; multiple near-term catalysts

Lupin Ltd.

BOB Capital Markets Ltd.

Lupin's (LPC) Q2 EBITDA was 5% below estimates.

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Lupin Ltd.

15 Oct 2020

1954.00

-0.27%

BP Equities Pharmaceuticals Result Preview Q2 FY21

Buy: Lupin Ltd.

Target

BP Wealth

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

30 Sep 2020

1954.00

-0.27%

Event Update - Tykerb : First generic launch

Buy: Lupin Ltd.

Prabhudas Lilladhar

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

25 Aug 2020

1954.00

-0.27%

Event Update - US FDA approval of gProAir HFA to lift earnings - BUY

Buy: Lupin Ltd.

Target

Prabhudas Lilladhar

LPC received approval for gProAir HFA (Albuterol Sulfate) that offers a revenue opportunity of US$140-155m over next 8 quarters beginning from 2QFY21E. The total market size of Albuterol Sulfate Inhalation Aerosol is US$2.9bn of which 44% market share is held by ProAir. While there are 9 companies in Albuterol (including 3 AG, 6 generics), LPC and Perrigo are the only generics in gProAir and plans to launch their generics in Aug CY20. We expect LPC can potentially have 5% Rx share of the Albuterol Sulfate...

Lupin Ltd. is trading below all available SMAs

Lupin Ltd.

12 Aug 2020, 12:00AM

1954.00

-0.27%

LUPIN LIMITED

Sell: Lupin Ltd.

Target

Geojit BNP Paribas

Lupin Limited is a multi-national pharmaceutical company based in Mumbai. The company specializes in branded and generic formulations, API's and advanced drug delivery systems in the area of biotechnology. The...

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Lupin Ltd.

10 Aug 2020

1954.00

-0.27%

Lupin Ltd

Sell: Lupin Ltd.

Target

Karvy

Outlook & Valuation: We downgrade our revenue estimates by 1% for FY21E to Rs. 168 Bn on account of downgrade in India and other key markets while we upgrade by 0.4% to Rs. 187 Bn on account of upgrade in key markets.

Lupin Ltd. has an average target of 2326.00 from 8 brokers.

Is Lupin Ltd. worth buying?

926 Votes:

Buy 72.79%

Sell 17.49%

Hold 9.72%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf